Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 02, 2015 1:35 AM ET

Life Sciences Tools and Services

Company Overview of Myriad RBM, Inc.

Company Overview

Myriad RBM, Inc., a multiplexed immunoassay testing laboratory, provides multi-analyte profile (MAP) technology platform based protein biomarker products and services for research, drug, and diagnostic development projects. Its products and services include HumanMAP services that assist investigators in the discovery, validation, and clinical use of biomarker patterns in biological samples, such as serum or plasma; and RodentMAP services that provide quantitative measurement of various biomarkers to enable new pattern discovery, as well as sensitive safety and efficacy assessments. The company’s products and services also comprise single molecule array technology based Ultrasensitive Immunoa...

3300 Duval Road

Austin, TX 78759

United States

Founded in 2002

141 Employees





Key Executives for Myriad RBM, Inc.

Age: 60
Chief Medical Officer
Age: 62
Vice President of IS & Technology
Managing Director of Communications
Vice President of Corporate Development
Compensation as of Fiscal Year 2015.

Myriad RBM, Inc. Key Developments

Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform

Myriad RBM announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples. Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The company has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) that are available from its CLIA-certified laboratory in Austin, Texas. Each assay includes carefully designed calibrators and controls to provide multiple measurements of quality, precision and accuracy. Myriad RBM plans to add more Simoa-based immunoassays throughout the year.

Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis

Myriad RBM announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative (SATVI) clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture® system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis. Myriad RBM will supply the study with its revolutionary TruCulture collection systems. Once the blood samples are collected, Myriad RBM and the Institut Pasteur will seek to discover protein biomarkers important in regulating the immune system response using Myriad RBM's proprietary MAP (Multi-Analyte Profiling) platform.

Institut Pasteur and Myriad RBM Publish Initial Results from Study of Immune Response

Institut Pasteur and Myriad RBM announced they have published an initial data analysis from the Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response. The Milieu Interieur project is a population-based study supported by the French National Ministry of Research and coordinated by the Institut Pasteur, Paris that will characterize the immune phenotypes of 1,000 healthy subjects. The results could lead to the development of novel diagnostics and companion diagnostics. In the paper titled, 'Functional Analysis using Standardized Whole Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli,' the authors describe the use of Myriad RBM's TruCulture(r) technology, a proprietary blood collection and culturing system, to characterize individual immune responses of 25 healthy people to medically relevant stimuli. Unlike the current laboratory-based methods, TruCulture is deployed at the site of collection and therefore avoids variability from shipping and complex processing as well as the expense of a cell culture facility and staff. The results in the Immunity paper show that TruCulture stimulations are reproducible, with close correspondence in repeated tests from the same subject.

Similar Private Companies By Industry

Company Name Region
PYRAMID Laboratories, Inc. United States
Applied Precision Inc. United States
PsyPharma Global, LLC United States
Complete Genomics, Inc. United States
Rosa & Co. LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Myriad RBM, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at